

## Enspryng

Dubai · access guide

# How to access Enspryng from Dubai, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Dubai patient recently diagnosed with neuromyelitis optica spectrum disorder (NMOSD) may receive a prescription for Enspryng (satralizumab-mwge) from their treating neurologist or neuroimmunology specialist. Enspryng is FDA-approved for the treatment of NMOSD in adult patients who are anti-aquaporin-4 (AQP4) antibody positive, and it is manufactured by Genentech (Roche). It targets the interleukin-6 (IL-6) receptor, a distinct mechanism from anti-CD19 B-cell depletion or terminal complement inhibition, and uniquely among approved NMOSD biologics it is administered subcutaneously, which makes long-term maintenance substantially more home-friendly. In Dubai, Enspryng may not yet be broadly registered, which is why your neurologist may be navigating a named-patient import pathway with you.

This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.

## The clinical situation

Enspryng is a humanised anti-IL-6 receptor monoclonal antibody administered as a 120 mg subcutaneous injection. The induction schedule is weeks 0, 2, and 4, followed by maintenance every four weeks. Eligibility typically requires confirmed AQP4-IgG seropositivity, a pre-treatment screening bundle (hepatitis B, tuberculosis, liver function, lipid profile, and up-to-date vaccinations), and exclusion of active infection. Your treating neurologist confirms diagnosis and supervises the injection schedule per FDA labeling.

## Is Enspryng legally importable into the Dubai?

Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. The pathway allows a the Dubai-licensed (under DHA) physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.

For Enspryng specifically, the application benefits from the subcutaneous administration route, there is no infusion-centre bottleneck, though the first dose is typically administered or observed in a clinical setting. Maintenance doses can be given at home by a trained patient or caregiver.

## How the pathway works, step by step

---

1. **Consultation with your treating neurologist.** AQP4-IgG confirmation, NMOSD clinical diagnosis, and pre-treatment screening (hepatitis B, TB, LFTs, lipid panel, vaccinations).
2. **MoHAP named-patient application.** Your physician files the application including clinical letter, patient identifier, and product details.
3. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure the product from the manufacturer's authorised distribution chain.
4. **Cold-chain shipment.** Enspryng ships at 2-8°C with continuous temperature monitoring.
5. **Arrival and administration.** The treating centre administers or observes the first dose; subsequent doses may be home-administered under physician supervision.

## What documentation your physician needs

---

Your physician will typically need to provide:

- Clinical rationale letter confirming NMOSD diagnosis and AQP4-IgG seropositivity with supporting MRI and clinical evidence
- Verification of the DHA medical licence (Dubai emirate)
- Patient identifier
- Pre-treatment screening results (hepatitis B, TB, LFTs, lipid panel, vaccination record)
- Planned induction (weeks 0, 2, 4) and four-weekly maintenance schedule

Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for NMOSD monoclonal-antibody therapy.

## Costs and timing

---

Enspryng's US cash-pay drug-only reference price sits in a broad indicative range, the annualised treatment cost sits in the USD 200,000-300,000 range in US list pricing, depending on dosing frequency after the loading period. International cold-chain logistics, MoHAP documentation, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake. Indicative range.

Indicative timing for the first dose after cohort intake opens is 7-14 days from the moment a complete application is submitted. Screening lead time may extend this.

*Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.*

## Reserve Meds's role

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Enspryng specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- **Documentation.** Regulatory package for your physician and for MoHAP review.
- **Logistics.** Cold-chain, temperature-monitored shipment.
- **Concierge case lead.** A named point of contact.

**What we do not do:** We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.

## Frequently asked

---

**Is this legal in Dubai?** Yes, when executed through the MoHAP named-patient framework with appropriate documentation.

**How does Enspryng compare with Uplizna or Soliris for NMOSD?** All three are FDA-approved for AQP4-IgG-positive NMOSD. Enspryng blocks IL-6R (subcutaneous, q4-weeks after loading); Uplizna depletes CD19 B cells (IV, q6-months); Soliris inhibits terminal complement (IV, q2-weeks). Enspryng's subcutaneous route is often preferred for long-term maintenance in patients who prefer home administration. Your neurologist chooses based on disease severity, infusion logistics, and comorbidities.

**Can I inject at home?** After the first dose is administered or supervised in a clinical setting and your neurologist is satisfied with technique, most patients can self-inject or have a caregiver inject at home.

**Will private insurance cover this?** Cash-pay is the default. Some Dubai private insurers reimburse NMOSD therapy on escalated review; we supply documentation but do not process insurance claims directly.

### *Reserve Meds's role*

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### **Reserve Meds**

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com